SNHG3 and ovarian carcinoma: Additionally, increased SNHG3 was associated with poor progression-free survival (PFS) in bladder cancer [6], metastasis-free survival (MFS) [19] and bone metastasis-free survival (BMFS) [32] in ovarian cancer.